Zentalis Pharmaceuticals ZNTL 深 沪
等待开盘 08-25 09:30:00 美东时间
3.76
-0.065
-1.70%
华盛通- 最 高3.96
- 今 开3.84
- 成交量 98.87万股
- 最 低 3.75
- 昨 收 3.825
- 总市值 3.56亿
- 52周最高 6.95
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 1.212
- 委 比 58.94%
- 总股本 9467.19万
- 历史最高 87.19
- 量 比 0.72
- 振 幅 5.49%
- 历史最低 1.01
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform ...
08-20 16:53
Stocks to watch on Thursday after hours: AMAT, DLO, ZNTL
Wall Street's benchmark S&P 500 pushed up to yet another all-time trading high on Thursday as investors digested July producer price data that showed wholesale inflation was unchanged from the previou...
08-14 04:28
Zentalis Pharmaceuticals shares are trading lower after the company announced a proposed public offering.
Zentalis Pharmaceuticals shares are trading lower after the company announced a proposed public offering.
08-14 04:25
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
<p>Zentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and pre-funded warrants. The company plans to use the net proceeds, along with existing cash, to fund clinical trials, regulatory filings, manufacturing, and other corporate purposes. The offering is subject to market conditions, and the underwriters have a 30-day option to purchase additional shares. The offering is bei...
08-13 20:01
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Zentalis Pharmaceuticals announced key updates on the advancement of azenosertib, a WEE1 inhibitor for ovarian cancer, including the completion of DENALI Part 2a and 2b enrollment, with Part 2c ongoing. The company expects top-line data from DENALI Part 2 in 1H 2027. Financially, Zentalis reported $174.6 million in cash as of June 2026, supporting operations into late 2027. Regulatory discussions with the FDA support the potential for accelerated...
08-06 20:05
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted 84,000 non-qualified stock options to two new employees under its 2022 Inducement Plan. The options, exercisable at $4.65 per share, vest over four years with 25% after the first year and the remaining 75% in monthly installments over the next three years. Zentalis is a clinical oncology innovator advancing a first-in-class WEE1 inhibitor for ovarian cancer treatment.
08-03 21:00
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
美股大行评级 | 台积电、联合健康、美国合众银行获多家大行上调目标价；奈飞、直觉外科遭数十家大行下调目标价
今日重点评级关注：摩根大通：维持联合大陆航空"超配"评级，目标价从156美元升至203美元；摩根士丹利：维持联合大陆航空"超配"评级，目标价从185美元升至190美元
07-20 13:49
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8
Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $8.
07-17 19:23
